Please login to the form below

Not currently logged in

BTK inhibitor

This page shows the latest BTK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Sanofi gains access to antibody tech with Kymab acquisition

Sanofi gains access to antibody tech with Kymab acquisition

Principia’s lead candidate and focus of the acquisition was Bruton tyrosine kinase (BTK) inhibitor ‘168, currently in development for the treatment of multiple sclerosis (MS). ... In 2017, Sanofi signed a deal with Principia for exclusive rights to

Latest news

More from news
Approximately 2 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica. ... Its BTK inhibitor zanubrutinib was granted Fast Track designation by the US FDA in

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

  • Deal Watch January 2018

    Collaboration, licence. 380. Jiangsu Hengrui Medicine/TG Therapeutics. BTK inhibitor programme, incl lead candidate TG-1701 (p1) and another BTK inhibitor (pc). ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Deal Watch November 2015 Deal Watch November 2015

    Overall 2015 has been a very busy year for Hanmi which in March closed a $690m deal with Lilly for a phase 1 BTK-inhibitor in autoimmune indications and also in ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration, licence. Sotagliflozin, p3 oral

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...